Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sangamo Therapeutics (SGMO) Goodwill (2016 - 2022)

Sangamo Therapeutics has reported Goodwill over the past 10 years, most recently at $37.6 million for Q4 2022.

  • Quarterly results put Goodwill at $37.6 million for Q4 2022, down 5.42% from a year ago — trailing twelve months through Dec 2022 was $37.6 million (down 5.42% YoY), and the annual figure for FY2022 was $37.6 million, down 5.42%.
  • Goodwill for Q4 2022 was $37.6 million at Sangamo Therapeutics, up from $34.5 million in the prior quarter.
  • Over the last five years, Goodwill for SGMO hit a ceiling of $42.8 million in Q4 2020 and a floor of $1.6 million in Q1 2018.
  • Median Goodwill over the past 5 years was $39.3 million (2019), compared with a mean of $33.7 million.
  • Biggest five-year swings in Goodwill: surged 2426.44% in 2018 and later dropped 14.85% in 2022.
  • Sangamo Therapeutics' Goodwill stood at $40.0 million in 2018, then decreased by 1.93% to $39.3 million in 2019, then grew by 8.98% to $42.8 million in 2020, then fell by 7.23% to $39.7 million in 2021, then fell by 5.42% to $37.6 million in 2022.
  • The last three reported values for Goodwill were $37.6 million (Q4 2022), $34.5 million (Q3 2022), and $36.7 million (Q2 2022) per Business Quant data.